Physician profile
Corey Cavanaugh
NPI 1114345162
$35,375.06
in general payments reported to CMS, 2019-2025
7 companies · $25K in 2025
The $25K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $118 · 2023: $351 · 2024: $9,326 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Travel and Lodging: $2,740 · Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,220.00 |
| Travel and Lodging | $2,739.85 |
| Food and Beverage | $1,968.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $23,371.06 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $6,451.29 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $4,378.28 | 2025 | |
| Jazz Pharmaceuticals INC. | $909.49 | 2021-2024 | |
| Amgen INC. | $142.50 | 2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $88.68 | 2021 | |
| Calliditas Therapeutics US INC. | $33.76 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Cavanaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.